Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Alliance Pharma plc    APH   GB0031030819

ALLIANCE PHARMA PLC (APH)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Alliance Pharma : first-half revenue rises on strong sales abroad

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 09:13am CET

(Reuters) - British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

(Reuters) - British speciality pharmaceutical company Alliance Pharma Plc (>> Alliance Pharma plc) on Wednesday reported an 8.4 percent rise in first-half revenue, helped by international sales of its scar reduction product and eye supplement.

The company, listed on London's junior stock market, said revenue rose to 50.3 million pounds for the six months ended June 30, from 46.4 million pounds a year ago.

Underlying profit before tax rose 1.7 percent to 11.9 million pounds during the period.

Sales of the company's top-selling scar-diminishing product, Kelo-cote, rose to 6.2 million pounds in the first half from 4.1 million pounds a year ago.

MacuShield, the company's nutritional supplement to treat age-related vision loss, posted a 67 percent rise in first-half sales at 3.4 million pounds.

Alliance Pharma, which bought the healthcare assets of Sinclair Pharma (>> Sinclair Pharma PLC) for 128 million pounds in December 2015, now owns about 90 pharmaceutical and healthcare products.

"With the integration of the Sinclair Pharma products now complete we are strategically positioned for growth and, with leverage levels reducing, we are now able to pursue bolt-on acquisitions," Chairman Andrew Smith said.

Alliance Pharma said it believed there were grounds to re-open discussions with the UK's medicinal product regulator on Diclectin, a drug for nausea during pregnancy, which failed to receive approval earlier this year.

However, analysts have said the regulatory decision meant the company was also looking for a replacement for Diclectin.

The replacement is likely to come via acquisition or by obtaining licenses from other companies rather from within the current portfolio, analysts have said.

(Reporting By Justin George Varghese in Bengaluru; Editing by Amrutha Gayathri)

Stocks treated in this article : Alliance Pharma plc, Sinclair Pharma PLC
Stocks mentioned in the article
ChangeLast1st jan.
SINCLAIR PHARMA PLC -0.22% 22.8 Delayed Quote.-12.73%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLIANCE PHARMA PLC
02/08ALLIANCE PHARMA : Notification of Preliminary Results
PU
01/22ALLIANCE PHARMA : Pre-Close Trading Update
PU
01/02ALLIANCE PHARMA : Completion of Acquisition of Vamousse®
PU
01/02ALLIANCE PHARMA : Block Listing Six Monthly Return
PU
2017ALLIANCE PHARMA : Completion of acquisition of Vamousse
PU
2017ALLIANCE PHARMA : Block Listing Six Monthly Return
PU
2017ALLIANCE PHARMA PLC : Ex-dividend day for for interim dividend
FA
2017ALLIANCE PHARMA : Proposed acquisition of Vamousse®
PU
2017ALLIANCE PHARMA : Tender Offer to Shareholders and Notice of Meeting
PU
2017ALLIANCE PHARMA : Proposed acquisition of Vamousse
PU
More news
Financials ( GBP)
Sales 2017 104 M
EBIT 2017 27,5 M
Net income 2017 22,8 M
Debt 2017 73,5 M
Yield 2017 1,95%
P/E ratio 2017 13,75
P/E ratio 2018 14,89
EV / Sales 2017 3,73x
EV / Sales 2018 3,18x
Capitalization 313 M
Chart ALLIANCE PHARMA PLC
Duration : Period :
Alliance Pharma plc Technical Analysis Chart | APH | GB0031030819 | 4-Traders
Technical analysis trends ALLIANCE PHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 0,76  GBP
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
John Dawson CEO, Director & Head-Investor Relations
Andrew Leonard Smith Chairman
Stephen Kidner Chief Scientific & Operations Officer
Andrew Timothy Franklin Chief Financial Officer, Director & IR Contact
Thomas Theodore Casdagli Non-Executive Director
Sector and Competitors